keyword
MENU ▼
Read by QxMD icon Read
search

Bendamustine

keyword
https://www.readbyqxmd.com/read/29908231/haploidentical-bone-marrow-transplantation-with-post-transplant-cyclophosphamide-bendamustine-in-pediatric-and-young-adult-patients-with-hematologic-malignancies
#1
Emmanuel Katsanis, Lauren N Sapp, Nicole Varner, Shannon Koza, Baldassarre Stea, Yi Zeng
More than half of patients undergoing hematopoietic cell transplantation at our institution are ethnic or racial minorities, making the search for matched unrelated donors more challenging. Since the introduction of haploidentical bone marrow transplant (haplo-BMT) into our pediatric BMT program in 2015, 69.2% of the recipients have been minorities. Herein, we describe our experience with the first thirteen pediatric and young adult patients with hematologic malignancies who have undergone T-cell replete haplo-BMT following myeloablative conditioning (MAC) at our institution...
June 13, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29898619/cost-effectiveness-of-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-monotherapy-for-the-treatment-of-follicular-lymphoma-patients-who-relapse-after-or-are-refractory-to-a-rituximab-containing-regimen-in-the-us
#2
Gregory F Guzauskas, Anthony Masaquel, Carolina Reyes, Coen Bernaards, Tania Krivasi, David L Veenstra
AIMS: Obinutuzumab (GA101, G) was approved in February 2016 by the U.S. Food and Drug Administration to treat follicular lymphoma (FL) patients who relapsed after, or are refractory to (R/R), a rituximab-containing regimen (R/R-rituximab). In the GADOLIN trial, R/R-rituximab patients who received G plus bendamustine (B) followed by G-monotherapy (G+B) for up to 2 years had significantly improved progression-free survival and overall survival compared to patients receiving B-monotherapy...
June 13, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29877929/presentation-and-management-of-the-delayed-type-of-hypersensitivity-reaction-with-bendamustine
#3
Sufana Shikdar, David Totton, Thomas Turco, Michael Rachshtut
Bendamustine, an alkylating agent with cytotoxic properties, has been increasingly employed in the treatment of chronic lymphocytic leukemia (CLL) either as a single agent or combination with rituximab. Although rarely reported, they can potentially cause hypersensitivity reactions with serious consequences. The objective of the case report was to offer a safe and effective bendamustine desensitization protocol to patients with a hypersensitivity reaction to this drug. We report a case of a patient with a CLL who developed a type IV hypersensitivity reaction to bendamustine and who was successfully treated by drug desensitization...
June 5, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29800121/increased-risk-of-infectious-complications-in-older-patients-with-indolent-non-hodgkin-lymphoma-exposed-to-bendamustine
#4
Monica Fung, Eric Jacobsen, Arnold Freedman, Daniel Prestes, Dimitrios Farmakiotis, Xiangmei Gu, Paul L Nguyen, Sophia Koo
Background: Bendamustine is a potent chemotherapy agent increasingly used to treat indolent non-Hodgkin lymphoma (iNHL). While effective, it causes significant T-cell lymphopenia, which may increase risk of infection. We examined infectious complications associated with bendamustine-containing regimens among older patients with iNHL. Methods: For this SEER-Medicare cohort study, we identified 9,395 patients with iNHL (follicular, marginal zone, Waldenström's macroglobulinemia) treated with chemotherapy from 2006-2013...
May 25, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29799642/high-dose-bendamustine-eam-followed-by-autologous-stem-cell-rescue-results-in-long-term-remission-rates-in-lymphoma-patients-without-renal-toxicty
#5
Thomas Noesslinger, Michael Panny, Ralph Simanek, Michaela Moestl, Alexandra Boehm, Elisabeth Menschel, Elisabeth Koller, Felix Keil
BACKGROUND: Autologous Stem Cell Transplantation (ASCT) following BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning is standard of care in relapsed low- and high-grade B-cell lymphoma (DLBCL) and other lymphoproliferative disorders, but BCNU is associated with interstitial pneumonia and an increased mortality. A less toxic regimen might improve the outcome of lymphoma patients after transplantation. OBJECTIVES: We investigated the role of bendamustine replacing BCNU in the BEAM regimen in lymphoma patients undergoing ASCT...
May 25, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29794145/lenalidomide-plus-bendamustine-rituximab-does-not-overcome-the-adverse-impact-of-tp53-mutations-in-mantle-cell-lymphoma
#6
Christian Winther Eskelund, Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Lone Bredo Pedersen, Christian Hartmann Geisler, Mats Jerkeman, Kirsten Grønbæk
No abstract text is available yet for this article.
May 24, 2018: Haematologica
https://www.readbyqxmd.com/read/29787919/optimal-use-of-novel-agents-in-chronic-lymphocytic-leukemia
#7
Mitchell R Smith, Robert F Weiss
Novel agents are changing therapy for patients with CLL, but their optimal use remains unclear. We model the clinical situation in which CLL responds to therapy, but resistant clones, generally carrying del17p, progress and lead to relapse. Sub-clones of varying growth rates and treatment sensitivity affect predicted therapy outcomes. We explore effects of different approaches to starting novel agent in relation to bendamustine-rituximab induction therapy: at initiation of therapy, at the end of chemo-immunotherapy, at molecular relapse, or at clinical detection of relapse...
May 7, 2018: Leukemia Research
https://www.readbyqxmd.com/read/29770488/an-efficient-and-facile-synthesis-of-deuterium-labeled-anticancer-agent-bendamustine-hydrochloride
#8
Baomin Liu, Hui Qin, Yinsheng Zhang
Bendamustine hydrochloride is an alkylating agent which was developed for the treatment of various human cancers. The stable isotope-labeled bendamustine was required to support clinic studies. An effective and operationally simple method for the synthesis of [D6 ] bendamustine hydrochloride was developed using DCl as a catalyst and D2 O as a deuterium source. Under the present condition, regioselectively deuterated bendamustine hydrochloride with high deuterium incorporation is achieved.
May 17, 2018: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29761908/rituximab-maintenance-therapy-of-follicular-lymphoma-in-clinical-practice
#9
Ulrich Dührsen, Stefanie Broszeit-Luft, Annette Dieing, Andreas Lück, Piotr Porowski, Marcel Reiser, Ulrike Schwinger, Sandra Klawitter, Katja Krumm, Kathleen Jentsch-Ullrich
Standard of care for patients with symptomatic, advanced-stage follicular lymphoma (FL) is rituximab-containing chemoimmunotherapy followed by rituximab maintenance. This prospective, multicenter, noninterventional study analyzed how efficacy and safety data from randomized controlled trials translate into clinical practice in Germany. Both treatment-naïve and relapsed/refractory patients with FL, who responded to rituximab-containing induction and were scheduled for rituximab maintenance, were observed for 24 months...
May 15, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29749403/obinutuzumab-plus-bendamustine-in-previously-untreated-patients-with-cll-a-subgroup-analysis-of-the-green-study
#10
Stephan Stilgenbauer, Veronique Leblond, Robin Foà, Sebastian Böttcher, Osman Ilhan, Wolfgang Knauf, Eva Mikuskova, Christoph Renner, Eugen Tausch, Dariusz Woszczyk, Ekaterina Gresko, Linda Lundberg, Tom Moore, Thea Morris, Susan Robson, Francesc Bosch
GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab-bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2-6; and bendamustine 70/90 mg/m2 D1 and D2 of C1-6. The primary endpoint was safety/tolerability...
April 27, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29748444/rituximab-plus-bendamustine-as-front-line-treatment-in-frail-elderly-70-years-patients-with-diffuse-large-b-cell-non-hodgkin-s-lymphoma-a-phase-ii-multicenter-study-of-the-fondazione-italiana-linfomi
#11
Sergio Storti, Michele Spina, Emanuela Anna Pesce, Flavia Salvi, Michele Merli, Alessia Ruffini, Giuseppina Cabras, Annalisa Chiappella, Emanuele Angelucci, Alberto Fabbri, Anna Marina Liberati, Monica Tani, Gerardo Musuraca, Annalia Molinari, Maria Pia Petrilli, Carmela Palladino, Rosanna Ciancia, Andrea Ferrario, Cristiana Gasbarrino, Federico Monaco, Vincenzo Fraticelli, Annalisa De Vellis, Francesco Merli, Stefano Luminari
We conducted a phase II study to assess activity and safety profile of bendamustine and rituximab in elderly patients with untreated Diffuse Large B Cell Lymphoma who were prospectively defined as frail using a simplified version of a Comprehensive Geriatric Assessment. Patients had to be > 70 years of age, with histologically confirmed Diffuse Large B Cell Lymphoma. Frail patients were those younger than 80 years with a frail profile at Comprehensive Geriatric Assessment or older than 80 years with an unfit profile...
May 10, 2018: Haematologica
https://www.readbyqxmd.com/read/29724299/comparison-of-antiemetic-effects-of-granisetron-and-palonosetron-in-patients-receiving-bendamustine-based-chemotherapy
#12
M Uchida, T Nakamura, Y Makihara, K Suetsugu, H Ikesue, Y Mori, K Kato, M Shiratsuchi, K Hosohata, T Miyamoto, K Akashi
The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed...
May 1, 2018: Die Pharmazie
https://www.readbyqxmd.com/read/29703778/brentuximab-vedotin-plus-bendamustine-a-highly-active-first-salvage-regimen-for-relapsed-or-refractory-hodgkin-lymphoma
#13
Ann S LaCasce, R Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M Ansell, Howland E Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A O'Connor, Neil Josephson, Yinghui Wang, Ranjana Advani
Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline chemotherapy. Achievement of complete remission (CR) with pre-ASCT salvage chemotherapy predicts favorable outcomes post-ASCT. This phase 1/2 study evaluated the combination of brentuximab vedotin (BV) plus bendamustine as a first salvage regimen in relapsed/refractory HL. A total of 55 patients (28 primary refractory and 27 relapsed) were enrolled. Patients received BV (1...
April 27, 2018: Blood
https://www.readbyqxmd.com/read/29695404/establishment-and-characteristics-of-a-novel-mantle-cell-lymphoma-derived-cell-line-and-a-bendamustine-resistant-subline
#14
Tomoko Takimoto-Shimomura, Hisao Nagoshi, Saori Maegawa, Yuto Fujibayashi, Taku Tsukamoto, Yayoi Matsumura-Kimoto, Yoshimi Mizuno, Yoshiaki Chinen, Shinsuke Mizutani, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Tsutomu Kobayashi, Junya Kuroda
BACKGROUND/AIM: Bendamustine hydrochloride (BH) is a key therapeutic agent for mantle cell lymphoma (MCL), while the mechanism underlying BH-resistance has not been verified. MATERIALS AND METHODS: We compared molecular/biological characteristics of a newly-generated MCL-derived cell line KPUM-YY1 and its BH-resistant subline KPUM-YY1R. RESULTS: The growth-inhibitory IC50 for BH was 20 μM in KPUM-YY1 cells, while cell proliferation was not inhibited by up to 60 μM BH in KPUM-YY1R cells...
May 2018: Cancer Genomics & Proteomics
https://www.readbyqxmd.com/read/29681187/assessment-of-bendamustine-induced-genotoxicity-in-eukaryotic-cells
#15
Tais Susane Pereira, Juliane Rocha de Sant'anna, Janicelle Fernandes Morais, Joana Paula Rocha de Sant'anna Yajima, Paulo Cezar de Freitas Mathias, Claudinéia Conationi da Silva Franco, Marialba Avezum Alves de Castro-Prado
Bendamustine, an anticancer drug with alkylating properties, is widely used to treat hematological malignancies. Since the nitrogen mustard family alkylators induce DNA damages and have been associated with an elevated risk of second malignancy, current study evaluates the cytotoxic, mutagenic, and recombinogenic effects of bendamustine by using, respectively the mitotic index assay, the in vitro mammalian cell micronucleus test (Mnvit) and the chromosome aberration (CA) test in human peripheral lymphocytes, and the in vivo homozygotization assay in Aspergillus nidulans, which detects the loss of heterozygosity (LOH) due to somatic recombination...
April 23, 2018: Drug and Chemical Toxicology
https://www.readbyqxmd.com/read/29674504/efficacy-of-bendamustine-and-rituximab-as-first-salvage-treatment-in-chronic-lymphocytic-leukemia-and-indirect-comparison-with-ibrutinib-a-gimema-eric-and-uk-cll-forum-study
#16
Antonio Cuneo, George Follows, Gian Matteo Rigolin, Alfonso Piciocchi, Alessandra Tedeschi, Livio Trentin, Angeles Medina Perez, Marta Coscia, Luca Laurenti, Gerardo Musuraca, Lucia Farina, Alfredo Rivas Delgado, Ester Maria Orlandi, Piero Galieni, Francesca Romana Mauro, Carlo Visco, Angela Amendola, Atto Billio, Roberto Marasca, Annalisa Chiarenza, Vittorio Meneghini, Fiorella Ilariucci, Monia Marchetti, Stefano Molica, Francesca Re, Gianluca Gaidano, Marcos Gonzalez, Francesco Forconi, Stefania Ciolli, Agostino Cortelezzi, Marco Montillo, Lukas Smolej, Anna Schuh, Toby A Eyre, Ben Kennedy, Kris M Bowles, Marco Vignetti, Javier de la Serna, Carol Moreno, Robin Foà, Paolo Ghia
We performed an observational study on the efficacy of bendamustine and rituximab as first salvage regimen in chronic lymphocytic leukemia. In an intention-to-treat analysis including 237 patients, the median progression free survival was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter progression free survival at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis...
April 19, 2018: Haematologica
https://www.readbyqxmd.com/read/29673920/-sinusoidal-obstruction-syndrome-after-beam-conditioning-regiment-for-autologous-stem-cell-transplantation-imputability-of-bendamustine-report-of-two-cases-and-literature-review
#17
A Meyer, L-M Fornecker, A Guffroy, A-S Korganow, M Martin
INTRODUCTION: Sinusoidal obstruction syndrome is a rare complication of autologous hematopoietic stem cell transplantation. This syndrome is mainly described following conditioning regiment with busulfan, cyclophosphamide and/or total body irradiation. CASE REPORTS: We report for the first time two cases of sinusoidal obstruction syndrome occurring lately after BeAM conditioning regiment (bendamustine, etoposide, aracytine, melphalan) for autologous stem cell transplantation in patients treated for malignant lymphoma...
April 16, 2018: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/29651368/synchronous-pulmonary-neoplasms-a-chance-occurrence-or-is-there-more-than-meets-the-eye
#18
Uroosa Ibrahim, Amina Saqib, Manisha Pant, Gwenalyn Garcia, Marcel Odaimi
Primary bronchus-associated lymphoid tissue (BALT) lymphoma comprises 5% of non-Hodgkin's lymphoma (NHL) and usually has an indolent course. Synchronous primary lung cancers with BALT lymphoma are seldom seen in patients with adenocarcinoma of the lung. Synchronous squamous cell carcinoma (SCC) and BALT lymphoma is an extremely rare occurrence. We report an unusual case of stage 4 BALT lymphoma requiring treatment that revealed an underlying ipsilateral mass causing a diagnostic dilemma. An 84-year-old female with a history of systemic lupus erythematosus, deep vein thrombosis, and thrombotic microangiopathy presented to the hospital with cough and dyspnea on exertion...
February 6, 2018: Curēus
https://www.readbyqxmd.com/read/29623625/applying-a-multicriteria-decision-analysis-mcda-approach-to-elicit-stakeholders-preferences-in-italy-the-case-of-obinutuzumab-for-rituximab-refractory-indolent-non-hodgkin-lymphoma-inhl
#19
Martina Garau, Grace Hampson, Nancy Devlin, Nicola Amedeo Mazzanti, Antonio Profico
BACKGROUND: Healthcare decision makers need to make trade-offs between different elements of value of new treatments. Multicriteria decision analysis (MCDA) provides a framework that can help decision makers to understand stakeholders' preferences and be explicit about the trade-offs that are being made. OBJECTIVE: The objective of this study was to use MCDA to obtain preferences and views on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to use these to assess the performance of obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL)...
June 2018: PharmacoEconomics open
https://www.readbyqxmd.com/read/29619501/bendamustine-plus-rituximab-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-multicenter-retrospective-analysis
#20
Jung Yong Hong, Dok Hyun Yoon, Cheolwon Suh, Won Seog Kim, Seok Jin Kim, Jae-Cheol Jo, Jin Seok Kim, Won-Sik Lee, Sung Yong Oh, Yong Park, Sung-Yong Kim, Mark Hong Lee, Ho Sup Lee, Young Rok Do
Bendamustine plus rituximab (BR) showed efficacy and safety in indolent lymphomas and mantle cell lymphoma. However, there were limited experiences of real-world practice of BR in diffuse large B cell lymphoma (DLBCL). In this study, we report the Korean experiences with BR in relapsed or refractory DLBCL who are not eligible for intensive chemotherapy and autologous stem cell transplantation. This is an observational, multicenter, retrospective analysis. Between December 2011 and December 2015, a total of 58 patients with relapsed or refractory DLBCL were treated with BR in 11 tertiary hospitals in Korea...
April 4, 2018: Annals of Hematology
keyword
keyword
80869
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"